[go: up one dir, main page]

WO2004022033A1 - Technique et dispositif d'apport commande d'hormone parathyroide - Google Patents

Technique et dispositif d'apport commande d'hormone parathyroide Download PDF

Info

Publication number
WO2004022033A1
WO2004022033A1 PCT/US2003/027770 US0327770W WO2004022033A1 WO 2004022033 A1 WO2004022033 A1 WO 2004022033A1 US 0327770 W US0327770 W US 0327770W WO 2004022033 A1 WO2004022033 A1 WO 2004022033A1
Authority
WO
WIPO (PCT)
Prior art keywords
parathyroid hormone
reservoir
release
reservoirs
pth
Prior art date
Application number
PCT/US2003/027770
Other languages
English (en)
Inventor
Dennis Ausiello
John T. Santini, Jr.
Stephen J. Herman
James H. Prescott
Original Assignee
Microchips, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microchips, Inc. filed Critical Microchips, Inc.
Priority to AU2003278766A priority Critical patent/AU2003278766A1/en
Publication of WO2004022033A1 publication Critical patent/WO2004022033A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0097—Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms

Definitions

  • This invention is generally in the field of methods and devices for the controlled delivery of parathyroid hormone (PTH) to patients, for example, to promote the growth and maintenance of bone tissue.
  • PTH parathyroid hormone
  • the mechanism of bone loss is not completely understood, but the disorder effectively arises from an imbalance in the formation of new healthy bone and the resorption of old bone.
  • the bone loss includes a decrease in both mineral content and protein matrix components of the bone, and leads to an increased rate of bone fracture.
  • fractures predominantly femoral bones and bones in the forearm and vertebrae, lead to an increase in general morbidity and a loss of stature and mobility, as well as an increase, in many cases, in mortality caused by complications from the fracture.
  • Bone loss occurs, for example, in post-menopausal women, patients who have undergone hysterectomy, patients undergoing or who have undergone long-term administration of corticosteroids, patients suffering from Cushing's syndrome, and patients having gonadal dysgenesis. Unchecked bone loss can lead to osteoporosis, a major debilitating disease whose prominent feature is the loss of bone mass
  • Post-menopausal osteoporosis is associated with the large and rapid loss of bone mass due to the cessation of estrogen production by the ovaries.
  • PTH is involved in calcium and skeletal homeostasis. It stimulates the tubular reso ⁇ tion of calcium by the kidney and inhibits the reabso ⁇ tion of phosphate and bicarbonate by the proximal renal tubules. PTH also affects the kidney by stimulating production of a vitamin D metabolite (l,25(OH)2D), which is an in vivo stimulator of osteoclasts and an enhancer of intestinal calcium abso ⁇ tion. The increase in intestinal calcium abso ⁇ tion following PTH stimulation is mediated by this vitamin D metabolite. In vivo, PTH stimulates osteoclastic bone reso ⁇ tion with the release of calcium into the circulation, and causes proliferation of osteoblasts.
  • l,25(OH)2D vitamin D metabolite
  • U.S. Patent No. 6,239,144 discloses that there is a dose dependent stimulation of the mineral apposition rate by PTH and that the result of the administration of PTH on skeletal homeostasis depends on how the hormone is administered. For the same daily dose, the bone volume shows a dose dependent increase if the daily dose of the hormone is given as one single injection. However, when the same daily dose is administered by continuous infusion with a subcutaneous mini-osmotic pump, the result is bone loss. Intermittent injection causes practically no effect on the serum calcium levels, whereas infusion causes a dose dependent increase in the serum calcium.
  • controlled or sustained drug delivery There are myriad technologies generally referred to as providing controlled or sustained drug delivery, which deliver drug by a variety of routes. Although some controlled release methods and devices have been somewhat effective in controlling protein or peptide delivery in the body, several limitations can influence their suitability or practicality for administering a particular therapeutic agent, such as PTH. For example, many "controlled" release dmg delivery systems may not provide a well-defined release profile. Other technologies may be suitable for continuous release (e.g., an ALZETTM osmotic pump), but not pulsatile release. Yet other technologies that are suitable for delivery of small molecule drugs would be unsuitable for long-term storage and delivery of fragile protein or peptide drug molecules.
  • Such molecules may, for example, undergo degradation and denaturation associated with exposure to moisture, elevated temperatures (e.g., 37 °C), and/or by other means.
  • Still other dmg delivery systems undesirably would require periodic (frequent) replacement or refilling, or an unacceptably large size in order to provide for the administration of drag for long-term therapy.
  • a drug delivery system capable of accurately delivering a therapeutically and/or prophylactically effective amount of PTH, alone or in combination with other drags. It desirably would provide well- defined pulsatile release of PTH over an extended period of time in a small, anatomically acceptable configuration, without requiring refilling of the delivery device with drug, repeated injections, or repeated replacement of part or the entire device over the course of treatment. In addition, it would be desirable for the drag delivery rate to be adjustable over the course of treatment.
  • Method and devices are provided for extended and controlled delivery of parathyroid hormone to a patient, for example, for the treatment and prevention of bone loss, such as associated with osteoporosis.
  • the method includes implanting a medical device into the patient, the medical device comprising a substrate, a plurality of reservoirs in the substrate, a release system contained in each of the reservoirs, wherein the release system comprises parathyroid hormone; and controUably releasing a pharmaceutically effective amount of the parathyroid hormone from the reservoirs.
  • the step of controUably releasing provides intermittent release of the parathyroid hormone.
  • the parathyroid hormone is released in a pulsatile manner, each pulse having a duration of less than four hours.
  • the parathyroid hormone is released daily in intermittent doses of between about 10 and 300 ⁇ g. In one embodiment, the daily intermittent doses are released over a period often months or more.
  • the pharmaceutically effective amount of the parathyroid hormone, released over a first period of time is effective to form bone tissue.
  • the method further includes releasing a pharmaceutically effective amount of a bone reso ⁇ tion inhibitor, released over a second period of time, to maintain bone tissue at a level present after the first period of time.
  • the bone reso ⁇ tion inhibitor is selected from the group consisting of bisphosphonates, selective estrogen receptor modulators, calcitonins, vitamin D analogs, and calcium salts.
  • the implantable device for the extended, controlled delivery of parathyroid hormone to a patient comprises a substrate, a plurality of reservoirs in the substrate, a release system contained in each of the reservoirs, wherein the release system comprises parathyroid hormone, and a control means for selectively releasing a pharmaceutically effective amount of the parathyroid hormone from each of the reservoirs.
  • the device releases a pharmaceutically effective amount of parathyroid hormone once daily over a period of at least six months.
  • the device further includes at least one reservoir which contains a second release system comprising a drag other than parathyroid hormone.
  • the drug could be an anti-reso ⁇ tive agent.
  • each of the reservoirs contains between about 10 and 40 ⁇ g of parathyroid hormone for release.
  • the device includes 300 or more reservoirs, each containing a release system comprising parathyroid hormone.
  • the release system comprises parathyroid hormone in combination with a pharmaceutically acceptable excipient.
  • the release system could include parathyroid hormone suspended in a non-aqueous vehicle.
  • the PTH could be dried or lyophilized with an excipient that promotes re-dissolution upon release.
  • an excipient could be for example, polyethylene glycol having a molecular weight between about 100 and 10,000 Daltons.
  • the control means includes reservoir caps covering the release system of the reservoirs.
  • the control means further comprises means for actively disintegrating or permeabilizing the reservoir caps.
  • the means for actively disintegrating comprises a power source for passing an electric current or potential through the reservoir caps.
  • the reservoir caps comprise an electrically conductive material and are electrically connected to an electrical input lead and to an electrical output lead, and the means for actively disintegrating or permeabilizing the reservoir cap comprises means for selectively applying an electrical current through the reservoir cap, via the input lead and output lead, in an amount effective to locally heat the reservoir cap to cause the reservoir cap to disintegrate to permit release of the parathyroid hormone.
  • the means for actively disintegrating the reservoir cap comprises a cathode, a microprocessor, a timer, and a demultiplexer, and wherein the reservoir caps each comprise an anode and upon application of an electric potential between the cathode and anode the reservoir cap disintegrates to permit release of the parathyroid hormone.
  • the device includes a sensor, such as one that measures plasma calcium.
  • control means comprises two or more layers of release system having different compositions.
  • Such an embodiment can effectively provide a passive control system for effecting pulsatile release.
  • Figure 1 is a perspective view of one embodiment of an implantable active- release microchip device for delivery of parathyroid hormone.
  • Figure 2 is a perspective view of another embodiment of an implantable active-release microchip device for delivery of parathyroid hormone.
  • Figure 3 is a cross-sectional view of one embodiment of a passive release microchip device for delivery of parathyroid hormone.
  • Figures 4A and 4B are cross-sectional views of two of the many possible embodiments of substrate/reservoir geometries: straight walled reservoirs ( Figure 4 A) and combination straight and tapered walled reservoirs (Figure 4B).
  • Figure 5 is a cross-sectional view of one embodiment of a passive release device substrate having a layered release system for controlling release as well as for controlling aggregation and precipitation of PTH.
  • Figure 6 is a plan view of one embodiment of the medical device described herein for intravaginal delivery of PTH.
  • Figure 7 is a cross-sectional view of the device shown in Figure 6.
  • Implantable medical devices have been developed for the controlled delivery of parathyroid hormone.
  • the device comprises a substrate comprising a plurality of reservoirs; a release system comprising parathyroid hormone contained in the reservoirs; and a means for controUably releasing a pharmaceutically effective amount of the parathyroid hormone from the reservoirs.
  • the medical device comprises a microchip device.
  • a microchip is a miniaturized device fabricated using methods described in U.S. Patents No. 5,797,898 and No. 6,123,861, to Santini, Jr.
  • the device includes a substrate having a plurality of reservoirs, which contain the PTH and, optionally, other drag molecules.
  • the substrate, reservoirs, reservoir caps, control circuitry, and power source are described at least in part herein and/or in U.S. Patents No. 5,797,898, No. 6,123,861, No. 6,551,838, No. 6,491,666, and No. 6,527,762, as well as U.S. Patent Application Publications No. 2002/0138067, No. 2002/0072784, No. 2002/0151776, and No. 2002/0107470.
  • control of reservoir cap opening includes electro-thermal ablation techniques, as described in U.S. Patent Application No. 10/641,507, filed August 15, 2003.
  • the substrate is the structural body (e.g., part of a device) in which the reservoirs are formed, e.g., it contains the etched, machined, or molded reservoirs.
  • a reservoir is a well, a container.
  • JMEMS methods, micromolding, and micromachining techniques known in the art can be used to fabricate the substrate/reservoirs from a variety of materials. See, for example, U.S. Patent No. 6,123,861 and U.S. Patent Application Publication No. 2002/0107470.
  • suitable substrate materials include metals, ceramics, semiconductors, and degradable and non-degradable polymers. Biocompatibility of the substrate material typically is preferred for in vivo device applications.
  • the substrate, or portions thereof, may be coated, encapsulated, or otherwise contained in a biocompatible material (e.g., poly(ethylene glycol), polytetrafluoroethylene-like materials, inert ceramics, titanium, and the like) before use.
  • a biocompatible material e.g., poly(ethylene glycol), polytetrafluoroethylene-like materials, inert ceramics, titanium, and the like
  • the substrate can be flexible or rigid.
  • the substrate serves as the support for a microchip device.
  • the substrate is formed of silicon.
  • the substrate can have a variety of shapes, or shaped surfaces. It can, for example, have a release side (i.e., an area having reservoir caps) that is planar or curved.
  • the substrate may, for example, be in a shape selected from disks, cylinders, or spheres.
  • the release side can be shaped to conform to a curved tissue surface or into a body lumen.
  • the back side distal the release side is shaped to conform to an attachment surface.
  • the substrate may consist of only one material, or may be a composite or multi-laminate material, that is, composed of several layers of the same or different substrate materials that are bonded together.
  • the substrate is hermetic, that is impermeable (at least during the time of use of the reservoir device) to the molecules to be delivered and to surrounding gases or fluids (e.g., water, blood, electrolytes or other solutions).
  • gases or fluids e.g., water, blood, electrolytes or other solutions.
  • the substrate is made of a strong material that degrades or dissolves over a defined period of time into biocompatible components.
  • biocompatible polymers include poly(lactic acid)s, poly(glycolic acid)s, and poly(lactic-co-glycolic acid)s, as well as degradable poly(anhydride-co-imides).
  • the substrate thickness can vary depending upon the particular device and application using the activation system described herein.
  • the thickness of a device may vary from approximately 10 ⁇ m to several millimeters (e.g., 500 ⁇ m).
  • Total substrate thickness and reservoir volume can be increased by bonding or attaching wafers or layers of substrate materials together.
  • the device thickness may affect the volume of each reservoir and/or may affect the maximum number of reservoirs that can be inco ⁇ orated onto a substrate.
  • the size and number of substrates and reservoirs can be selected to accommodate the quantity and volume of reservoir contents needed for a particular application, although other constraints such as manufacturing limitations or total device size limitations (e.g., for implantation into a patient) also may come into play.
  • devices for in vivo applications desirably would be small enough to be implanted using minimally invasive procedures.
  • the device would be appropriately sized to be inserted into the vagina for intravaginal administration of PTH.
  • the substrate includes at least two and preferably tens or hundreds of reservoirs.
  • one reservoir could be provided for each daily dose of PTH required, for example, over a 6-, 8-, 10-, or 12-month course of treatment.
  • the substrate could include, for example, 300 to 400 reservoirs, each containing a release system comprising parathyroid hormone.
  • the reservoir has a volume equal to or less than 500 ⁇ L (e.g., less than 250 ⁇ L, less than 100 ⁇ L, less than 50 ⁇ L, less than 25 ⁇ L, less than 10 ⁇ L, etc.) and greater than about 1 nL (e.g., greater than 5 nL, greater than 10 nL, greater than about 25 nL, greater than about 50 nL, greater than about 1 ⁇ L, etc.).
  • 500 ⁇ L e.g., less than 250 ⁇ L, less than 100 ⁇ L, less than 50 ⁇ L, less than 25 ⁇ L, less than 10 ⁇ L, etc.
  • 1 nL e.g., greater than 5 nL, greater than 10 nL, greater than about 25 nL, greater than about 50 nL, greater than about 1 ⁇ L, etc.
  • FIGS 4 A and 4B Two of the many possible embodiments of substrate/reservoir geometries are illustrated in Figures 4 A and 4B.
  • the embodiment shown in Figure 4 A shows substrate 45 having reservoirs 46a and 46b, which are covered by reservoir caps 47a and 47b, respectively. Reservoirs 46a and 46b have straight, i.e. non-tapered, walls.
  • the embodiment shown in Figure 4B shows a laminate substrate, composed of lower portion 45a and upper portion 45b, which has reservoirs 48a and 48b, which are covered by reservoir caps 47a and 47b, respectively. Reservoirs 48a and 48b have a combination of straight walls in the lower portion 45a of the substrate and tapered walls in the upper portion 45b of the substrate. Drag and Release System
  • the release system comprises a pharmaceutical formulation of the parathyroid hormone.
  • release system includes the situations where the PTH molecules are in pure form (e.g., as a lyophilized powder), in suspension, in solution, or in a matrix formed of biodegradable material or another material which releases inco ⁇ orated PTH molecules by diffusion or disintegration of the matrix.
  • the release system can, for example, include excipients that modulate the rate of release of PTH.
  • parathyroid hormone or "PTH” includes the complete human hormone (hPTH 1-84); fragments of the hormone responsible for bone growth promotion, such as hPTH 1-34 and hPTH 1-38, and analogs in which the amino acid sequence is modified slightly, yet retain bone growth promotion properties, such as PTH-RP; and synthetic and/or recombinant biologically active peptide derivatives of parathyroid hormone (e.g., hPTH(l-28)), such as described in U.S. Patent No. 6,417,333 to Bringhurst et al.
  • the PTH may be native or synthesized by chemical or recombinant means.
  • the PTH may or may not be in lyophilized form, depending upon the desired formulation and storage requirements.
  • the PTH could be provided in a lyophilized salt form, such as a chloride or acetate (e.g., as hPTH(l-34)Cl or PTH(1- 34)OAc), which could be sealed in the reservoirs under nitrogen gas with low water content, without excipient.
  • lyophilized PTH can be suspended in a non-solvent (e.g., non-aqueous) vehicle.
  • the PTH can be inco ⁇ orated into micelles or liposomes.
  • the release system comprises PTH dried or lyophilized with an excipient that promotes re-dissolution upon release. Such a composition would accelerate the rate of release (i.e., reduce the pulse duration).
  • An example of a suitable excipient in this embodiment is polyethylene glycol having a molecular weight between about 100 and 10,000 Daltons.
  • the release system includes PTH in (e.g., in a mixture with) a pharmaceutically acceptable excipient.
  • the term "excipient" is used broadly to include virtually any suitable drug delivery vehicle.
  • the excipient may be a solvent or non-solvent for the PTH to prepare a solution or suspension of the PTH, respectively.
  • the solvent or non-solvent may be aqueous or non-aqueous, so long as the PTH is substantially stable in the solution or suspension during storage in the reservoirs of the drag delivery device and for the useful lifetime of the device.
  • the PTH is provided in suspension with a non-aqueous vehicle suitable for stable storage.
  • Preferred pharmaceutically acceptable excipients include non-aqueous vehicles suitable for suspension and stable storage of PTH at 37 °C for several months, preferably a year or more.
  • the non-aqueous vehicle could be an anhydrous, aprotic, hydrophobic, non-polar liquid, with low reactivity to PTH.
  • Representative examples of non-aqueous vehicles include biocompatible perhalohydrocarbons or unsubstituted saturated hydrocarbons.
  • Examples of these include perfluorodecalin, perflurobutylamine, perfluorotripropylamine, perfluoro-N- methyldecahydroquindine, perfluoro-octohydro quinolidine, perfluoro-N- cyclohexylpyrilidine, perfluoro-N,N-dimethylcyclohexyl methylamine, perfluoro- dimethyl-adamantane, perfluorotri-methylbicyclo (3.3.1) nonane, bis(perfluorohexyl) ethene, bis(perfluorobutyl) ethene, perfluoro- l-butyl-2-hexyl ethene, tetradecane, methoxyflurane and mineral oil.
  • the PTH is provided in a solution.
  • a non- aqueous (anhydrous) solvent that may be suitable is DMSO (dimethyl sulfoxide).
  • the release system comprises PTH dried or lyophilized with an excipient that would promote re-dissolution upon release, such as polyethylene glycol having a molecular weight between about 100 and 10,000 Daltons.
  • PTHDosage The devices can be used to deliver essentially any medically indicated dosage of PTH. In one embodiment, PTH dosages are between 0.5 and 1.0 ⁇ g/(kg-day).
  • the PTH advantageously is released in daily pulsatile doses of between 10 and 300 ⁇ g.
  • each reservoir could contain a single dose, e.g., about 20 ⁇ g PTH (1-34) or about 100 to 200 ⁇ g PTH (1-84) in a suitable formulation.
  • Release dosages can be varied by a number of techniques, for example, by providing different quantities of drag among different reservoirs (some reservoirs contain 20 ⁇ g of PTH, and others contain 10, 15, or 40 ⁇ g of PTH) and/or by combining various numbers of reservoirs to form a single dose (e.g., simultaneously opening two reservoirs each containing 10 ⁇ g of PTH).
  • reservoirs may contain release system consisting or comprising other (non-PTH) drugs for release. These additional drags may be in the same reservoirs as the PTH or in different reservoirs.
  • these other drugs include bone reso ⁇ tion inhibitors, such as bisphosphonates (e.g., alendronate, risedronate sodium), estrogen, selective estrogen receptor modulators (e.g., raloxifene HC1), calcitonins, vitamin D analogs, and calcium salts.
  • the PTH is delivered (e.g., subcutaneously or intravaginally) from the implanted medical device described herein and the other drag, e.g., an anti-reso ⁇ tive agent, is administered orally using a conventional oral dosage form.
  • the PTH and the other drug(s) may be administered sequentially, concurrently, or simultaneously.
  • the drags may be in the form of solid mixtures including amo ⁇ hous and crystalline mixed powders, monolithic solid mixtures, lyophilized powders, and solid inte ⁇ enetrating networks.
  • the drags may, for example, be in the form of liquid mixtures, including solutions, emulsions, colloidal suspensions, and slurries, or in the form of gel mixtures, including hydrogels.
  • the term "reservoir cap” includes a membrane or other structure suitable for separating the contents of a reservoir from the environment outside of the reservoir. It generally is self-supporting across the reservoir opening, although caps having additional structures to provide mechanical support to the cap can be fabricated. Selectively removing the reservoir cap or making it permeable will then "expose" the contents of the reservoir to the environment (or selected components thereof) surrounding the reservoir. In preferred embodiments, the reservoir cap is selectively disintegrated.
  • the term "disintegrate” is used broadly to include without limitation degrading, dissolving, rapturing, fracturing or some other form of mechanical failure, as well as a loss of structural integrity due to a chemical reaction (e.g., electrochemical degradation) or phase change (e.g., melting) in response to a change in temperature, unless a specific one of these mechanisms is indicated.
  • the "disintegration” is by an electrochemical activation technique, such as described in U.S. Patent No. 5,797,898.
  • the "disintegration” is by an electro-thermal ablation technique, such as described in U.S. Patent Application No. 10/641,507, filed August 15, 2003.
  • the reservoir cap generally includes any material that can be disintegrated or permeabilized in response to an applied stimulus, e.g., electric field or current, magnetic field, change in pH, or by thermal, chemical, electrochemical, or mechanical means.
  • the reservoir cap is a thin metal film and is impermeable to the surrounding environment (e.g., body fluids or another chloride containing solution).
  • a particular electric potential is applied to the metal reservoir cap, which is then oxidized and disintegrated by an electrochemical reaction, to release the drag from the reservoir.
  • suitable reservoir cap materials include gold, silver, copper, and zinc.
  • the reservoir cap is heated (e.g., using resistive heating) to cause the reservoir cap to melt and be displaced from the reservoir to open it.
  • This latter variation could be used, for example, with reservoir caps formed of a metal or a non-metal material, e.g., a polymer.
  • the reservoir cap is formed of a polymer or other material that undergoes a temperature-dependent change in permeability such that upon heating to a pre-selected temperature, the reservoir is rendered permeable to the drug and bodily fluids to permit the drag to be released from the reservoir through the reservoir cap.
  • the reservoir cap is formed of a conductive material, such as a metal film, through which an electrical current can be passed to electrothermally ablate it, as described in U.S. Patent Application No. 10/641,507, filed August 15, 2003.
  • suitable reservoir cap materials include gold, copper, aluminum, silver, platinum, titanium, palladium, various alloys (e.g., Au/Si, Au/Ge, Pt-Ir, Ni-Ti, Pt-Si, SS 304, SS 316), and silicon doped with an impurity to increase electrical conductivity, as known in the art.
  • the reservoir cap is in the form of a thin metal film.
  • the reservoir cap is part of a multiple layer structure, for example, the reservoir cap can be made of multiple metal layers, such as a multi-layer/laminate structure of platinum/titanium/platinum.
  • the reservoir cap is operably (i.e. electrically) connected to an electrical input lead and to an electrical output lead, to facilitate flow of an electrical current through the reservoir cap.
  • an effective amount of an electrical current is applied through the leads and reservoir cap, the temperature of the reservoir cap is locally increased due to resistive heating, and the heat generated within the reservoir cap increases the temperature sufficiently to cause the reservoir cap to be electrothermally ablated (i.e., raptured).
  • the reservoir cap is formed from a material or mixture of materials that degrade, dissolve, or disintegrate over time, or that do not degrade, dissolve, or disintegrate, but are permeable or become permeable to molecules or energy.
  • Representative examples of reservoir cap materials include polymeric materials, and non-polymeric materials such as porous forms of metals, semiconductors, and ceramics.
  • Passive semiconductor reservoir cap materials include nanoporous or microporous silicon membranes.
  • the release system containing the molecules to be delivered is covered by a degradable cap material that is nearly impermeable to the molecules.
  • the time of release of the molecules from the reservoir will be limited by the time necessary for the cap material to degrade or dissolve.
  • the cap material is non-degradable and is permeable to the molecules to be delivered. The physical properties of the material used, its degree of crosslinking, and its thickness will determine the time necessary for the molecules to diffuse through the cap material. If diffusion out of the release system is limiting, the cap material delays the onset of release. If diffusion through the cap material is limiting, the cap material determines the release rate of the molecules in addition to delaying the onset of release.
  • a passive, layered release system to provide pulsatile release is used in combination with an actuatable reservoir cap.
  • Figure 3 illustrates a microchip device for the passive release of parathyroid hormone. It shows device 40 which includes substrate 41 having three reservoirs 42a, 42b, and 42c, which contain, respectively, release system 43a, 43b, and 43c, which are covered respectively, by bioerodible or biodegradable reservoir caps 44a, 44b, and 44c.
  • the thickness of the reservoir caps is different for each reservoir cap to provide different times of PTH release.
  • any combination of passive and/or active release reservoir cap can be present in a single microchip device.
  • the reservoir cap can be removed by electrothermal ablation to expose a passive release system that only begins its passive release after the reservoir cap has been actively removed.
  • a given substrate can include both passive and active release reservoirs.
  • Controlling Release The device preferably is provided with a control means to control the time at which the PTH or other drug is released from the device, and into the patient's body. At least for PTH, the control means should provide intermittent release, for example, daily over a period of months (e.g., 2, 6, 10, or preferably 12, months or more). The particular features of the control means depend on the mechanism of reservoir cap activation described herein.
  • control means can include the hardware, electrical components, and software needed to control and deliver the electric current from a power source to selected reservoir caps for actuation (i.e., opening).
  • the control means can include an input source, a microprocessor, a timer, a demultiplexer (or multiplexer), and a power source.
  • demultiplexer also refers to multiplexers.
  • the power source provides energy to activate the selected reservoir, i.e. trigger release of drag from the particular reservoir desired for a given dose.
  • the operation of the reservoir opening system can be controlled by an on-board microprocessor (e.g., the microprocessor is within an implantable or insertable device).
  • the microprocessor can be programmed to initiate the disintegration or permeabilization of the reservoir cap in response at a pre-selected time or in response to one or more of signals or measured parameters, including receipt of a signal from another device (for example by remote control or wireless methods) or detection of a particular condition using a sensor such as a biosensor.
  • a simple state machine is used, as it typically is simpler, smaller, and/or uses less power than a microprocessor.
  • the device can also be activated or powered using wireless means, for example, as described in U.S. 20020072784 Al to Sheppard et al.
  • the device includes a substrate having a two-dimensional array of reservoirs arranged therein, a release system comprising PTH contained in the reservoirs, anode reservoir caps covering each of the reservoirs, cathodes positioned on the substrate near the anodes, and means for actively controlling disintegration of the reservoir caps.
  • the means includes a power source and circuitry to control and deliver an electrical potential energy drives a reaction between selected anodes and cathodes.
  • the microprocessor directs power to specific electrode pairs through a demultiplexer as directed by a PROM, remote control, or biosensor.
  • the activation energy initiates a thermally driven rupturing or permeabilization process, for example, as described in PCT WO 01/12157.
  • the means for controlling release can actively disintegrate or permeabilize a reservoir cap using a resistive heater.
  • the resistive heater can cause the reservoir cap to undergo a phase change or fracture, for example, as a result of thermal expansion of the reservoir cap or release system, thereby rapturing the reservoir cap and releasing the PTH from the selected reservoir.
  • the application of electric current to the resistor can be delivered and controlled using components as described above for use in the electrochemical disintegration embodiment.
  • a microprocessor can direct current to select reservoirs at desired intervals.
  • control means controls electro-resistive ablation of the reservoir cap.
  • the drag delivery device could include a reservoir cap formed of an electrically conductive material, which prevents the PTH from passing out from the device; an electrical input lead connected to the reservoir cap; an electrical output lead connected to the reservoir cap; and a control means to deliver an effective amount of electrical current through the reservoir cap, via the input lead and output lead, to locally heat and rapture the reservoir cap to release the PTH.
  • the reservoir cap and conductive leads are formed of the same material, where the temperature of the reservoir cap increases locally under applied current because the reservoir cap is suspended in a medium that is less thermally conductive than the substrate.
  • the reservoir cap and conductive leads are formed of the same material, and the reservoir cap has a smaller cross-sectional area in the direction of electric current flow, where the increase in current density through the reservoir cap causes an increase in localized heating.
  • the reservoir cap alternatively can be formed of a material that is different from the material forming the leads, wherein the material forming the reservoir cap has a different electrical resistivity, thermal diffusivity, thermal conductivity, and/or a lower melting temperature than the material forming the leads. Various combinations of these embodiments can be employed.
  • Microelectronic device packages are typically made of an insulating or dielectric material such as aluminum oxide or silicon nitride. Low cost packages can also be made of plastics or reinforced epoxies (similar to those used in making printed circuit boards). Their pu ⁇ ose is to allow all components of the device to be placed in close proximity and to facilitate the interconnection of components to power sources and to each other, while protecting the electronics from the environment. Implanted microchip device packages will need to be hermetically sealed, e.g., in a titanium encasement, which essentially exposes only the reservoir caps.
  • the control means can include a microprocessor, a timer, a demultiplexer, and an input source (for example, a memory source, a signal receiver, or a biosensor), and a power source.
  • the timer and demultiplexer circuitry can be designed and inco ⁇ orated directly onto the surface of the microchip during electrode fabrication, or may be inco ⁇ orated in a separate microchip.
  • the criteria for selection of a microprocessor are small size, low power requirement, and the ability to translate the output from memory sources, signal receivers, or biosensors into an address for the direction of power through the demultiplexer to a specific reservoir on the microchip device.
  • a source of input to the microprocessor such as memory sources, signal receivers, or biosensors depends on the microchip device's particular application and whether device operation is preprogrammed, controlled by remote means, or controlled by feedback from its environment (i.e. biofeedback).
  • a microprocessor is used in conjunction with a source of memory such as erasable programmable read only memory (EPROM), a timer, a demultiplexer, and a power source such as a battery or a biofuel cell.
  • a source of memory such as erasable programmable read only memory (EPROM), a timer, a demultiplexer, and a power source such as a battery or a biofuel cell.
  • EPROM erasable programmable read only memory
  • timer erasable programmable read only memory
  • demultiplexer erasable programmable read only memory
  • a power source such as a battery or a biofuel cell.
  • a programmed sequence of events including the time a reservoir is to be opened and the location or address of the reservoir is stored into the EPROM by the user.
  • the microprocessor sends a signal corresponding to the address (location) of a particular reservoir to the demultiplexer.
  • the demultiplexer routes an input, such as an
  • the means for controUably releasing comprises the release system having different layers of disintegratable materials such that pulsatile release of the parathyroid hormone is provided by disintegration of the layers.
  • a single pulse from each reservoir using multiple reservoirs effectively provides a pulsatile release profile.
  • a pulsatile release profile can be provided from a single reservoir, for example, by inco ⁇ orating several layers of a release system and other materials into a single reservoir.
  • the reservoir caps can be formed from a material that degrades or dissolves over time, or does not degrade or dissolve, but is permeable to the PTH molecules to be delivered. These materials are preferably polymeric materials.
  • caps can be formed of different polymers (e.g., that dissolve at varying rates), the same polymer with different degrees of crosslinking, or a UV polymerizable polymer. In the latter case, varying the exposure of this polymer to UV light results in varying degrees of crosslinking and gives the cap material different diffusion properties or degradation or dissolution rates.
  • Another way to obtain different release times is by using one polymer, but varying the thickness of that polymer. Thicker films of some polymers result in delayed release time. Any combination of polymer, degree of crosslinking, or polymer thickness can be modified to obtain a specific release time or rate.
  • the layered release system technique described above for use in achieving a pulsatile PTH release profile advantageously and su ⁇ risingly has been found to aid in avoiding undesirable phenomena during release (e.g., aggregation, precipitation of PTH). It was found that when trying to release a solution of PTH at a low pH (e.g., pH 3) through a tiny reservoir opening (e.g., a square having 50 micron sides) and into a physiological solution (pH 7), the PTH could precipitate and block the reservoir opening.
  • a low pH e.g., pH 3
  • a tiny reservoir opening e.g., a square having 50 micron sides
  • the concentration of the PTH By varying the concentration of the PTH to account for the mass diffusion rate differences, precipitation of the PTH can be avoided, e.g., to keep the PTH concentration (and/or pH) at the reservoir opening sufficiently low. It is believed that the same technique could be used to prevent aggregation/precipitation of other proteins or peptides released from a micro-reservoir system.
  • the release system in a reservoir could comprise layers of different drug content and/or excipient which could effect release rates and localized drug concentrations within and adjacent the reservoir during release.
  • the reservoir release system comprises alternating layers of drag and non-drug materials.
  • Figure 5 illustrates device 50 comprising substrate 52 having reservoirs covered by reservoir caps 54 and containing a release system that consists of PTH-containing layers 56 which are alternated with excipient layers 58.
  • the layers comprises different concentrations of PTH, in accordance with the varying diffusion distances (and varying cross-sectional areas for reservoirs having tapered walls) in the reservoir.
  • a solid fill is needed, for example, where layers comprises a matrix material (e.g., in the form of a sol or gel) having drug dispersed therein.
  • the matrix material is a water-soluble, inert polymer, such as polyethylene glycol (PEG), which is solid at 37 °C.
  • the microchip device includes a sensor or sensing component.
  • the sensor or sensing component can be located in a reservoir or can be attached to the device substrate.
  • the sensor can operably communicate with the device, e.g., through a microprocessor, to control or modify the drug release variables, including dosage amount and frequency, time of release, effective rate of release, selection of drag or drag combination, and the like.
  • the "sensing component” includes a component utilized in measuring or analyzing the presence, absence, or change in a chemical or ionic species, energy, or one or more physical properties (e.g., pH, pressure). Types of sensors include biosensors, chemical sensors, physical sensors, or optical sensors.
  • the sensor or sensing component detects (or not) the species or property at the site of in vivo implantation (e.g., in a bodily fluid or tissue), and further may relay a signal to the microprocessor used for controlling release from the microchip device, as detailed below. Such a signal could provide feedback on and/or finely control the release of parathyroid hormone.
  • the senor measures plasma calcium levels in the patient and modulates release of PTH or other drags in response to the measured calcium level, and the amount of parathyroid hormone released from the microchip is dependent on the level of plasma calcium detected by such a sensor.
  • a calcium sensor is described in Van Den Burg, et al., "An ISFET-Based Calcium
  • the microchip device may also factor in other information in determining the amount and timing of PTH release.
  • bone density and hydroxyproline levels in the urine may be clinical indicators for PTH treatment, and the presence of hyperthyroidism or fluctuation in calcium homeostasis may relate to the increased calcium levels detected.
  • Such information can be transmitted to the microchip device, preferably wirelessly, from other sensors and/or from a physician inputting the information derived, for example, from diagnostic tests performed on the patient.
  • Active microchip devices may be controlled by local microprocessors or remote control.
  • Biosensor information may provide input to the controller to determine the time and type of activation automatically, with human intervention, or a combination thereof.
  • the operation of the microchip system will be controlled by an onboard (i.e. within the package) microprocessor.
  • the output signal from the device after conditioning by suitable circuitry if needed, will be acquired by the microprocessor.
  • the output signal can be stored in a writeable computer memory chip, and/or can be sent (e.g., wirelessly) to a remote location away from the microchip.
  • Power can be supplied to the microchip system locally by a microbattery or remotely by wireless transmission.
  • the microchip device includes one or more biosensors (which may be sealed in reservoirs until needed for use) that are capable of detecting and/or measuring signals within the body of a patient.
  • biosensor includes sensing devices that transduce the chemical potential of an analyte of interest into an electrical signal (e.g., an ion selective field effect transistor or ISFET), as well as electrodes that measure electrical signals directly or indirectly (e.g., by converting a mechanical or thermal energy into an electrical signal).
  • the biosensor may measure intrinsic electrical signals (EKG, EEG, or other neural signals), pressure, temperature, pH, or loads on tissue structures at various in vivo locations.
  • the electrical signal from the biosensor can then be measured, for example by a microprocessor/controller, which then can transmit the information to a remote controller, another local controller, or both.
  • a microprocessor/controller which then can transmit the information to a remote controller, another local controller, or both.
  • the system can be used to relay or record information on the patient's vital signs or the implant environment, such as drag concentration.
  • FIG. 1 shows, in a perspective view, microchip device 10, which includes substrate/reservoir portion 12 in a biocompatible package 14, such as a titanium encasement.
  • the package 14 further includes battery 16 and other device electronics.
  • Figure 1 also shows a close-up, in a perspective and partial cross-sectional view, of a portion of substrate/reservoir portion 12.
  • the close-up illustrates two reservoirs 22a and 22b in substrate 20, which contain release system 26 comprising parathyroid hormone.
  • the reservoirs 22a and 22b are covered by anodic reservoir caps 24a and 24b, respectively, which could be opened by an electrochemical degradation mechanism upon application of an electric potential between a cathode 25 and the anode reservoir caps.
  • FIG. 1 Another embodiment of an implantable active-release microchip device for delivery of PTH is illustrated in Figure 2.
  • FIG 1 shows, in a perspective view, microchip device 10, which includes substrate/reservoir portion 12 in a biocompatible package 14, such as a titanium encasement.
  • the package 14 further includes battery 16 and other device electronics.
  • the close-up view in Figure 2 also shows, in a perspective and partial cross-sectional view, a portion of substrate/reservoir portion 12, illustrating two reservoirs 28 and 32 in substrate 20, which contain release system 26 comprising parathyroid hormone.
  • the reservoirs 28 and 32 are covered by reservoir caps 28a and 32a, respectively.
  • Reservoir cap 28a is electrically connected to electrical input lead 28b and to electrical output lead 28c
  • reservoir cap 32a is electrically connected to electrical input lead 32b and to electrical output lead 32c.
  • Methods of Making the Medical Devices are described for example in U.S. Patent No. 5,797,898; U.S. Patent No. 6,123,861; U.S. Patent Application Publication No. 2002/0107470; U.S. Patent Application Publication No. 2002/0151776, and U.S. Patent Application Publication No. 2002/0183721, as well as U.S. Application No. 10/641,507.
  • a MEMS technique is used to make the substrate, reservoirs, and reservoir caps.
  • standard machining techniques such as drilling or laser machining are used to make the substrate and reservoirs.
  • soft lithography, microcontact printing, or the like is used.
  • these techniques can be useful for forming leads and reservoir caps on non-planar substrates. See, e.g., U.S. PatentNo. 6,180,239; No. 5,951,881; No, 6,355,198; and No. 6,518,168.
  • the assembly of a complete microchip drag delivery device involves a number of packaging steps, including (1) attachment of electrical leads to the substrate, (2) filling of the reservoirs with a release system comprising PTH, (3) sealing the reservoirs, (4) integration with electronic components and power sources, and (5) placing the microchip(s) and associated components within a single biocompatible enclosure or "package.”
  • the package optionally may be conformally coated with parylene or an inert ceramic material (see e.g., U.S. Patent Application Publication No. 2002/0187260).
  • insulating or dielectric materials are deposited over the reservoir cap, leads, or entire surface of the device by methods such as chemical vapor deposition (CVD), electron or ion beam evaporation, sputtering, or spin coating to protect the device or enhance biostability/biocompatibility.
  • CVD chemical vapor deposition
  • examples of such materials include oxides, nitrides, carbides, diamond or diamond-like materials, or fluorocarbon films.
  • the step of reservoir sealing and the step of formation of a reservoir cap over the reservoir opening can be combined. This is particularly useful for devices in which the reservoirs are filled and released from the same side, for example, in embodiments where the reservoirs are formed in a substrate without penetrating through the entire thickness of the substrate.
  • the reservoir is filled from an opening in the end of the reservoir distal the reservoir cap, and then this opening is permanently sealed.
  • the microchip devices and release methods described herein can be used to deliver (i.e., administer) parathyroid hormone to a patient for a variety of treatments.
  • the devices and methods can be used to reduce the incidence of bone fractures, defects, and disorders which result from weakened bones due to as osteoporosis, osteoarthritis, Paget's disease, osteohalisteresis, osteomalacia, bone loss resulting from multiple myeloma and other forms of cancer, bone loss resulting from side effects of other medical treatment (such as steroids), and age-related loss of bone mass.
  • the microchip device could be used for strengthening a bone graft, for treating prosthetic ingrowth such as promoting bone ingrowth into a bone prosthesis, for treating a bone fracture, or for treating childhood idiopathic bone loss in a child.
  • the term "patient” refers to a living vertebrate animal such as a mammal (e.g., human) in need of treatment, i.e., in need of bone repair, augmentation, or replacement.
  • treatment refers to (1) providing a patient with an amount of a substance sufficient to act prophylactically to prevent the development of a weakened and/or unhealthy state; (2) providing a patient with a sufficient amount of a substance so as to alleviate or eliminate a disease state and/or the symptoms of a disease state, and a weakened and/or unhealthy state; (3) providing a patient with an amount of a substance sufficient to promote bone formation; or (4) providing combinations of such substances.
  • the microchip device is implanted into the patient for long-term delivery of PTH, alone or in combination with other drags. "Long term” refers to release over an extended period (e.g., between 1 week and 3 years, between 6 weeks and 2 years, between 3 months and 1 year, etc.).
  • the microchip device can be implanted in vivo using standard surgical or minimally invasive implantation techniques, e.g., via a catheter, at any suitable site. Preferred sites include subcutaneous pectoral or abdominal sites. Depending upon the particular administration route or implantation site, the microchip device can be used for local, regional, or systemic delivery of PTH.
  • the medical device is adapted to deliver the PTH by the vaginal route.
  • the medical device could use active release or could rely solely on passive release to deliver the PTH.
  • a particular advantage of using the vaginal route of administration for delivering PTH is that deployment of the device is not surgical. No implantation procedure is necessary; rather the device is manually inserted into the vagina of the patient, not unlike a tampon or conventional vaginal ring device.
  • the device would be designed for more frequent replacement than would be desirable for a subcutaneous device. In such an embodiment, the device would not need to hold as much PTH as the device for subcutaneous implantation.
  • the control electronics and power source could also be simplified, thereby reducing the cost of the device.
  • the microchip device could be made to be very small and release daily doses of PTH for one or two months, after which time the device could be removed and replaced with a new one. If appropriate, treatment could be halted immediately at any time by simply removing the device.
  • the microchip device includes or is combined with a polymeric (e.g., medical grade silicone rubber) body, such as a strip-, rod-, or toras- shaped device.
  • the body can be, for example, in the form of a vaginal ring-like device (see e.g., U.S. Patent Application Publication No. 20020161352, U.S. Patent No. 4,822,616, and U.S. Patent No. 4,012,496, for description of vaginal rings that can be modified for use herein).
  • a patient or a caregiver can manually place the device into the vagina, where the device remains secured in place by contact (e.g., frictional engagement) with the vaginal walls.
  • the vaginal ring device could include a polymeric coating that is bioadhesive to mucosal surfaces. Preferably no suturing or other more permanent securing means would be required.
  • the vaginal ring/microchip device could include an expandable portion that expands upon insertion to enhance the frictional engagement with the vaginal walls.
  • the vaginal ring/microchip device is selected to have a size appropriate for a particular patient.
  • an array of discrete microreservoirs are fabricated directly into a vaginal ring body (which serves as the substrate), as illustrated in Figures 6-7.
  • the substrate is (integral with) the attachment body.
  • FIGS 6-7 show device 60 having ring-shaped body 62 in which a plurality of reservoirs containing a PTH formulation 66 are located.
  • the reservoirs are sealed by (generic) reservoir caps 64.
  • the reservoir caps may be opened by any of a number of passive or active techniques described herein.
  • Active control means can be embedded (e.g., within a compartment) in the ring-shaped body.
  • the body can be a multilayer structure, for example it could have a rigid core portion and a soft polymeric shell.
  • the drug-release side of the microchip device is positioned toward and in contact with the mucosal tissues of the vaginal wall. This facilitates transport of the drag from a reservoir, upon opening, to moist vaginal tissues, enabling the drug to diffuse into the capillaries and other small blood vessels in the tissue, for systemic delivery.
  • the PTH composition is formulated with a penetration enhancer or abso ⁇ tion promoter to enable such penetration, abso ⁇ tion, transfer or transport through the mucosa.
  • the PTH can be controUably released from one or more of the reservoirs, either actively or passively, in a pharmaceutically effective amount at the desired dosing schedule.
  • pharmaceutically effective refers to that amount which effects the formation and differentiation of bone.
  • each reservoir is loaded with between about 10 and about 300 ⁇ g of parathyroid hormone.
  • the microchip device delivers daily doses (pulses) of 20 ⁇ g/day of PTH (1-34) for one year, in order to grow bone, to restore lost bone mass.
  • the width (i.e., duration) of each pulse dose of PTH is selected to be a therapeutically effective period.
  • the duration of each pulse is less than four hours (e.g., less than three hours, less than two hours, less than one hour).
  • the patient would first receive PTH by injection for the first one or two months of therapy to ensure that the patient experiences no adverse reactions (e.g., hypercalcemia) to the PTH treatment.
  • the microchip device for PTH delivery would be implanted into the patient.
  • the microchip device would then provide administration of PTH, obviating the need for injections going forward.
  • a single microchip device provides least all of the PTH doses required over the course of therapy.
  • the device could contain enough PTH to provide daily doses for between about 10 months and about 12 months.
  • a treatment with one or more anti-reso ⁇ tive agents is typically begun.
  • the treatment could include daily doses of a chronic bone loss inhibitor, for up to five years.
  • the same device further provides some or all of the doses of anti- reso ⁇ tive agent.
  • the PTH is administered from the implanted microchip device, and the anti-reso ⁇ tive agent is administered by another route suitable for the selected anti-reso ⁇ tive agent, such as orally or by parental injection.
  • a single, non-refillable microchip device is provided with at least a year's supply of PTH for delivery.
  • the microchip device could have a substrate provided with a 400-reservoir array, with each reservoir containing a single dose, e.g., about 20 ⁇ g PTH (1-34) or about 100 to 200 ⁇ g PTH (1-84) in a suitable formulation.
  • a single dose e.g., about 20 ⁇ g PTH (1-34) or about 100 to 200 ⁇ g PTH (1-84) in a suitable formulation.
  • the microchip device can be controlled by a pre-programmed microprocessor to open a one or a portion of the reservoirs intermittently (that is, a different one or more reservoirs after each period) to effect release intermittently, e.g., in a pulsatile manner.
  • the microprocessor (and thus release) is controlled by a sensor, e.g., a biosensor, or by remote control.
  • the PTH can be controUably released using reservoir caps formed of a biodegradable material (e.g., a polymer, such as PLGA). Release times can be controlled and varied by altering the thicJkness of the reservoir cap, the composition of the reservoir cap (e.g., degree of crosslinking, etc.), or both.
  • a biodegradable material e.g., a polymer, such as PLGA.
  • another drug is released before, simultaneously with, or following one or more releases of PTH.
  • the other drag can be contained in the same reservoirs that contain the PTH or the other drug can be contained in one or more separate reservoirs.
  • the other drag can be controUably released in a continuous or intermittent manner.
  • PTH and raloxifene may be administered sequentially, concurrently, or simultaneously as a single composition to the patient. If administered sequentially, the period between the administration of PTH and raloxifene will typically be one week to one year, and optimally, one week to six months.
  • the patient will, after administration of PTH, with or without raloxifene, be administered raloxifene after cessation of administration of PTH.
  • the PTH is released intermittently from the microchip device during a period between 6 and 24 months, and then once PTH administration has been completely, a bone reso ⁇ tion inhibitor is released during a period between about 6 and 36 months.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une technique et des dispositifs d'apport prolongé et commandé d'hormone parathyroïde à un patient. Ce procédé consiste à implanter un dispositif médical dans l'anatomie de ce patient, ce dispositif médical comprenant un substrat, une pluralité de réservoirs placés dans ce substrat, un système de libération contenu dans chacun des réservoirs et ce système de libération comprenant une hormone parathyroïde et, à libérer de manière commandée une quantité phamaceutiquement efficace de cette hormone parathyroïde à partir de ces réservoirs. Cette hormone parathyroïde peut être libérée par intermittence, par exemple une fois par jour pendant une période assez longue (par exemple deux mois, 10 mois voire davantage). Ce dispositif peut aussi comprendre des réservoirs contenant un inhibiteur de résorption osseuse ou un autre médicament en vue d'une libération. Ces dispositif conviennent pour délivrer de la protéine liée à l'hormone parathyroïde (PTH) destinée au traitement et la prévention de perte osseuse, telle que celle qui est associée à l'ostéoporose.
PCT/US2003/027770 2002-09-04 2003-09-04 Technique et dispositif d'apport commande d'hormone parathyroide WO2004022033A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003278766A AU2003278766A1 (en) 2002-09-04 2003-09-04 Method and device for the controlled delivery of parathyroid hormone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40816502P 2002-09-04 2002-09-04
US60/408,165 2002-09-04

Publications (1)

Publication Number Publication Date
WO2004022033A1 true WO2004022033A1 (fr) 2004-03-18

Family

ID=31978569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027770 WO2004022033A1 (fr) 2002-09-04 2003-09-04 Technique et dispositif d'apport commande d'hormone parathyroide

Country Status (3)

Country Link
US (2) US7497855B2 (fr)
AU (1) AU2003278766A1 (fr)
WO (1) WO2004022033A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096176A2 (fr) * 2003-04-25 2004-11-11 Boston Scientific Scimed Inc. Formulation de medicament solide, et dispositif de stockage et de distribution controlee de ce medicament
WO2005079913A1 (fr) * 2004-02-19 2005-09-01 Silverleaf Medical Products, Inc. Piles et méthodes de fabrication et d’utilisation
WO2006085908A2 (fr) * 2004-06-01 2006-08-17 Microchips, Inc. Dispositifs et methodes de mesure et accroissement du transport de medicaments ou d'analytes vers ou depuis un implant medical
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US7662176B2 (en) 2004-02-19 2010-02-16 Vomaris Innovations, Inc. Footwear apparatus and methods of manufacture and use
EP2428486A2 (fr) 2004-11-04 2012-03-14 MicroCHIPS, Inc. Procédés et dispositifs d'étanchéité de soudage à froid et compression
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
EP2984912A4 (fr) * 2013-04-12 2017-01-25 The Board of Trustees of the University of Illionis Matériaux, systèmes électroniques et modes pour effet transitoire actif et passif
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
EP3658204A4 (fr) * 2017-07-24 2021-06-23 California Institute of Technology Barrière électriquement amovible, amplifiée chimiquement et à faible puissance

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4397558B2 (ja) * 1999-08-18 2010-01-13 マイクロチップス・インコーポレーテッド 熱駆動マイクロチップ化学送達デバイス
ATE499988T1 (de) 2000-03-02 2011-03-15 Microchips Inc Mikromechanische geräte und verfahren zur speicherung und zur selektiven exposition von chemikalien
CA2432438C (fr) 2001-01-09 2011-04-26 Microchips, Inc. Dispositifs flexibles a micropuces a usage ophtalmique ou autre
US6875208B2 (en) * 2001-05-31 2005-04-05 Massachusetts Institute Of Technology Microchip devices with improved reservoir opening
JP2005505429A (ja) * 2001-06-28 2005-02-24 マイクロチップス・インコーポレーテッド マイクロチップリザーバデバイスを密閉シーリングするための方法
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
KR100725973B1 (ko) * 2002-08-16 2007-06-11 마이크로칩스 인코포레이티드 전열적 제거를 이용한 제어 방출 장치 및 방법
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
EP1551499A1 (fr) * 2002-10-04 2005-07-13 Microchips, Inc. Dispositif medical de stimulation nerveuse et d'administration controlee de medicaments
DE60331455D1 (de) * 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
US7114312B2 (en) * 2003-07-17 2006-10-03 Microchips, Inc. Low temperature methods for hermetically sealing reservoir devices
WO2005041767A2 (fr) * 2003-11-03 2005-05-12 Microchips, Inc. Dispositif medical de detection du glucose
US7088010B2 (en) * 2003-12-18 2006-08-08 Intel Corporation Chip packaging compositions, packages and systems made therewith, and methods of making same
US20070036835A1 (en) * 2004-07-19 2007-02-15 Microchips, Inc. Hermetically Sealed Devices for Controlled Release or Exposure of Reservoir Contents
WO2006015299A2 (fr) * 2004-07-30 2006-02-09 Microchips, Inc. Dispositif multi-reservoir pour la delivrance de medicament transdermique et la detection
AU2005279729B2 (en) * 2004-09-01 2010-12-02 Microchips, Inc. Multi-cap reservoir devices for controlled release or exposure of reservoir contents
US20060093646A1 (en) * 2004-10-28 2006-05-04 Cima Michael J Orthopedic and dental implant devices providing controlled drug delivery
US7413846B2 (en) 2004-11-15 2008-08-19 Microchips, Inc. Fabrication methods and structures for micro-reservoir devices
EP1843783B1 (fr) * 2005-01-25 2012-05-30 MicroCHIPS, Inc. Regulation de la liberation de medicament par la modification transitoire de microenvironnements locaux
US8092548B2 (en) 2005-06-22 2012-01-10 Warsaw Orthopedic, Inc. Osteograft treatment to promote osteoinduction and osteograft incorporation
WO2007001624A2 (fr) * 2005-06-28 2007-01-04 Microchips, Inc. Dispositifs d’implants médicaux et dentaires pour administration contrôlée de médicaments
US20070123923A1 (en) * 2005-11-30 2007-05-31 Lindstrom Curtis C Implantable medical device minimizing rotation and dislocation
WO2008008845A2 (fr) * 2006-07-11 2008-01-17 Microchips, Inc. Dispositif multi-réservoirs à pompe pour dialyse, biodétection ou administration de substances
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
WO2008128140A1 (fr) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Dispositif d'administration et son procédé de fabrication
EP2052700A1 (fr) * 2007-09-26 2009-04-29 Microchips, Inc. Dispositif d'administration de médicaments et procédés à utiliser avec une implantation de dispositif prothétique.
US7869044B2 (en) * 2008-01-16 2011-01-11 Optotrace Technologies, Inc. Optical sensing system based on a micro-array structure
US9333329B2 (en) * 2008-03-04 2016-05-10 Elan Ziv Vaginal carrier for the controlled release of substances
US9017310B2 (en) * 2009-10-08 2015-04-28 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including microneedles
US8882748B2 (en) * 2009-10-08 2014-11-11 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including chemical permeation enhancers
US9014799B2 (en) * 2009-10-08 2015-04-21 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including electrically-actuated permeation enhancement
US8784858B2 (en) 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
US8911426B2 (en) * 2010-02-08 2014-12-16 On Demand Therapeutics, Inc. Low-permeability, laser-activated drug delivery device
AU2011200392B2 (en) * 2011-01-31 2015-05-28 Palo Alto Research Center Incorporated Transmucosal drug delivery device
CN102641548B (zh) * 2011-02-18 2016-08-03 帕洛阿尔托研究中心公司 包括化学品渗透增强剂的透粘膜药物输送装置和方法
US10427153B2 (en) 2011-08-25 2019-10-01 Microchips Biotech, Inc. Systems and methods for sealing a plurality of reservoirs of a microchip element with a sealing grid
PT2747642T (pt) 2011-08-25 2021-07-27 Microchips Biotech Inc Dispositivos de contenção eficientes em termos de espaço e método de criação dos mesmos
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013078422A2 (fr) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Préparations et thérapies de substitution pour hormonothérapie naturelle combinée
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9005108B2 (en) 2012-09-27 2015-04-14 Palo Alto Research Center Incorporated Multiple reservoir drug delivery device and methods
US9999720B2 (en) 2012-09-27 2018-06-19 Palo Alto Research Center Incorporated Drug reconstitution and delivery device and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2934289B1 (fr) 2012-12-21 2018-04-25 Microchips Biotech, Inc. Dispositif médical implantable pour insertion minimalement invasive
US9744341B2 (en) 2013-01-15 2017-08-29 Palo Alto Research Center Incorporated Devices and methods for intraluminal retention and drug delivery
CA2899076C (fr) 2013-02-28 2017-09-12 Microchips Biotech, Inc. Dispositif medical implantable pour insertion minimalement invasive
US20140276360A1 (en) * 2013-03-15 2014-09-18 Abbott Cardiovascular Systems Inc. Electrophorectic drug coated balloon and conductive polymer coating
US10292263B2 (en) 2013-04-12 2019-05-14 The Board Of Trustees Of The University Of Illinois Biodegradable materials for multilayer transient printed circuit boards
EP2991719A4 (fr) * 2013-05-02 2017-01-11 Elwha LLC Dispositif implantable pour manipuler des cellules immunes
US20140330257A1 (en) * 2013-05-02 2014-11-06 Elwha Llc Implantable Device for Manipulating Immune Cells
US9297083B2 (en) 2013-12-16 2016-03-29 Palo Alto Research Center Incorporated Electrolytic gas generating devices, actuators, and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9801660B2 (en) 2014-07-31 2017-10-31 Palo Alto Research Center Incorporated Implantable fluid delivery devices, systems, and methods
US10278675B2 (en) 2014-07-31 2019-05-07 Palo Alto Research Center Incorporated Implantable estrus detection devices, systems, and methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017083786A1 (fr) * 2015-11-11 2017-05-18 Elenza, Inc. Détecteur de calcium et implant
US10925543B2 (en) 2015-11-11 2021-02-23 The Board Of Trustees Of The University Of Illinois Bioresorbable silicon electronics for transient implants
IL260552B2 (en) * 2016-01-11 2024-05-01 Syqe Medical Ltd A personal vaporizer
WO2017173044A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
EP3435977A4 (fr) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde
WO2018104345A1 (fr) * 2016-12-06 2018-06-14 Roche Diabetes Care Gmbh Dispositif d'administration de médicament et station de transfert
WO2020159780A1 (fr) * 2019-02-01 2020-08-06 Analog Devices, Inc. Biocapteur sous-cutané
KR102316847B1 (ko) * 2019-09-24 2021-10-26 가톨릭관동대학교산학협력단 연골 재생용 스캐폴드
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05238929A (ja) * 1992-02-27 1993-09-17 Sumitomo Pharmaceut Co Ltd 代謝性骨疾患治療用長期持続性製剤
WO1998000107A2 (fr) * 1996-07-02 1998-01-08 Massachusetts Institute Of Technology Dispositifs d'administration de medicaments sur microplaquettes
US6306420B1 (en) * 1994-09-02 2001-10-23 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Methods and apparatus for the delivery of solid drug compositions
US20020107505A1 (en) * 1995-06-06 2002-08-08 Alza Corporation Modification of polypeptide drugs to increase electrotransport flux
WO2003032957A2 (fr) * 2001-06-28 2003-04-24 Microchips, Inc. Procede de fermeture hermetique de dispositifs a puits contenant des microplaquettes

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US641733A (en) * 1899-02-21 1900-01-23 George T Simpson Ironing-board.
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4833125A (en) 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
NO179479C (no) 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5317010A (en) 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
WO1994006452A1 (fr) * 1992-09-21 1994-03-31 The Upjohn Company Formulations de proteines a liberation prolongee
TW303299B (fr) 1993-07-22 1997-04-21 Lilly Co Eli
US5368704A (en) * 1993-08-06 1994-11-29 Teknekron Corporation Micro-electrochemical valves and method
US5496801A (en) 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US6110892A (en) 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5550134A (en) 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
DE19610293C1 (de) 1996-03-15 1997-07-31 Fraunhofer Ges Forschung Vorrichtung zur gekapselten Aufnahme eines Materials
WO1998003497A1 (fr) * 1996-07-22 1998-01-29 Novartis Ag Fluoroionophores immobilises de maniere covalente pour capteurs optiques d'ions
IN184589B (fr) 1996-10-16 2000-09-09 Alza Corp
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US5945412A (en) 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
WO1998043639A1 (fr) 1997-04-03 1998-10-08 Eli Lilly And Company Procedes pour traiter la deperdition osseuse
DE19716683C1 (de) 1997-04-21 1998-06-04 Fraunhofer Ges Forschung Vorrichtung zur getrennten, gekapselten Aufnahme einer Mehrzahl gleicher oder unterschiedlicher Stoffe
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
IL121286A0 (en) * 1997-07-11 1998-01-04 Pets N People Ltd Apparatus and methods for dispensing pet care substances
WO1999018945A1 (fr) 1997-10-14 1999-04-22 Eli Lilly And Company Procede de recalcification et de conservation osseuses
PL341209A1 (en) 1997-12-18 2001-03-26 Lilly Co Eli Crystalline teriparatide
AU1633200A (en) 1998-11-25 2000-06-13 General Hospital Corporation, The Human parathyroid hormone modifications, preparation and use
JP4397558B2 (ja) 1999-08-18 2010-01-13 マイクロチップス・インコーポレーテッド 熱駆動マイクロチップ化学送達デバイス
CA2392006C (fr) 1999-11-17 2011-03-15 Microchips, Inc. Dispositifs microfabriques pour transport de molecules dans un fluide porteur
ATE323470T1 (de) * 1999-12-10 2006-05-15 Massachusetts Inst Technology Mikrochip-arzneistoffverabreichungssysteme und herstellungsverfahren
ATE499988T1 (de) 2000-03-02 2011-03-15 Microchips Inc Mikromechanische geräte und verfahren zur speicherung und zur selektiven exposition von chemikalien
WO2001091902A2 (fr) 2000-05-30 2001-12-06 Massachusetts Institute Of Technology Procedes et dispositifs de fermeture hermetique de reservoirs a puce
US20040047910A1 (en) * 2000-07-07 2004-03-11 Christian Beckett Suppository and composition comprising at least one polyethylene glycol
US6387711B1 (en) 2000-08-11 2002-05-14 Quest Diagnostics Investments Incorporated Liquid intact parathyroid hormone (PTH) standards
WO2002030264A2 (fr) 2000-10-10 2002-04-18 Microchips, Inc. Systemes-reservoirs a micropuce utilisant la transmission sans fil d'energie et de donnees
AU2002224453A1 (en) 2000-10-11 2002-04-22 Microchips, Inc. Microchip reservoir devices and facilitated corrosion of electrodes
DE10063612C2 (de) 2000-12-20 2002-11-07 Fraunhofer Ges Forschung Mikrosystem zur Kontrolle der Wirkstoffabgabe aus einem Wirkstoffreservoir sowie Implantat mit Mikrosystem
CA2432438C (fr) 2001-01-09 2011-04-26 Microchips, Inc. Dispositifs flexibles a micropuces a usage ophtalmique ou autre
CN1210079C (zh) 2001-04-25 2005-07-13 上海市计划生育科学研究所 阴道环制剂及其应用
WO2002096389A1 (fr) 2001-05-30 2002-12-05 Microchips, Inc. Dispositifs reservoirs a micropuce pourvus d'un revetement conforme
US6875208B2 (en) 2001-05-31 2005-04-05 Massachusetts Institute Of Technology Microchip devices with improved reservoir opening
KR100725973B1 (ko) * 2002-08-16 2007-06-11 마이크로칩스 인코포레이티드 전열적 제거를 이용한 제어 방출 장치 및 방법
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
EP1551499A1 (fr) 2002-10-04 2005-07-13 Microchips, Inc. Dispositif medical de stimulation nerveuse et d'administration controlee de medicaments
AU2005279729B2 (en) * 2004-09-01 2010-12-02 Microchips, Inc. Multi-cap reservoir devices for controlled release or exposure of reservoir contents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05238929A (ja) * 1992-02-27 1993-09-17 Sumitomo Pharmaceut Co Ltd 代謝性骨疾患治療用長期持続性製剤
US6306420B1 (en) * 1994-09-02 2001-10-23 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Methods and apparatus for the delivery of solid drug compositions
US20020107505A1 (en) * 1995-06-06 2002-08-08 Alza Corporation Modification of polypeptide drugs to increase electrotransport flux
WO1998000107A2 (fr) * 1996-07-02 1998-01-08 Massachusetts Institute Of Technology Dispositifs d'administration de medicaments sur microplaquettes
WO2003032957A2 (fr) * 2001-06-28 2003-04-24 Microchips, Inc. Procede de fermeture hermetique de dispositifs a puits contenant des microplaquettes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 017, no. 704 (C - 1146) 22 December 1993 (1993-12-22) *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096176A3 (fr) * 2003-04-25 2005-03-24 Microchips Inc Formulation de medicament solide, et dispositif de stockage et de distribution controlee de ce medicament
WO2004096176A2 (fr) * 2003-04-25 2004-11-11 Boston Scientific Scimed Inc. Formulation de medicament solide, et dispositif de stockage et de distribution controlee de ce medicament
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US7813806B2 (en) 2004-02-19 2010-10-12 Vomaris Innovations, Inc. Current producing surface for treating biologic tissue
US7457667B2 (en) 2004-02-19 2008-11-25 Silverleaf Medical Products, Inc. Current producing surface for a wound dressing
US7662176B2 (en) 2004-02-19 2010-02-16 Vomaris Innovations, Inc. Footwear apparatus and methods of manufacture and use
US7672719B2 (en) 2004-02-19 2010-03-02 Vomaris Innovations, Inc. Batteries and methods of manufacture and use
WO2005079913A1 (fr) * 2004-02-19 2005-09-01 Silverleaf Medical Products, Inc. Piles et méthodes de fabrication et d’utilisation
US8224439B2 (en) 2004-02-19 2012-07-17 Vamaris Innovations, Inc. Batteries and methods of manufacture and use
WO2006085908A3 (fr) * 2004-06-01 2007-02-15 Microchips Inc Dispositifs et methodes de mesure et accroissement du transport de medicaments ou d'analytes vers ou depuis un implant medical
WO2006085908A2 (fr) * 2004-06-01 2006-08-17 Microchips, Inc. Dispositifs et methodes de mesure et accroissement du transport de medicaments ou d'analytes vers ou depuis un implant medical
EP2428486A2 (fr) 2004-11-04 2012-03-14 MicroCHIPS, Inc. Procédés et dispositifs d'étanchéité de soudage à froid et compression
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US9427400B2 (en) 2010-10-19 2016-08-30 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
EP2984912A4 (fr) * 2013-04-12 2017-01-25 The Board of Trustees of the University of Illionis Matériaux, systèmes électroniques et modes pour effet transitoire actif et passif
US10154592B2 (en) 2013-04-12 2018-12-11 The Board Of Trustees Of The University Of Illinois Materials, electronic systems and modes for active and passive transience
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US11259956B2 (en) 2013-11-14 2022-03-01 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US11793669B2 (en) 2013-11-14 2023-10-24 The Population Council, Inc. Combination therapy intravaginal rings
EP3658204A4 (fr) * 2017-07-24 2021-06-23 California Institute of Technology Barrière électriquement amovible, amplifiée chimiquement et à faible puissance
US11304893B2 (en) 2017-07-24 2022-04-19 California Institute Of Technology Low power, chemically amplified, electrically removable barrier
US11904045B2 (en) 2017-07-24 2024-02-20 California Institute Of Technology Low power, chemically amplified, electrically removable barrier

Also Published As

Publication number Publication date
US7497855B2 (en) 2009-03-03
US8277440B2 (en) 2012-10-02
US20090163895A1 (en) 2009-06-25
US20040082937A1 (en) 2004-04-29
AU2003278766A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
US7497855B2 (en) Method and device for the controlled delivery of parathyroid hormone
JP5313756B2 (ja) 制御された放出デバイスおよび方法
US7599737B2 (en) Medical device for neural stimulation and controlled drug delivery
EP1551505B1 (fr) Appareil medical pour administration controlee de medicament et surveillance et/ou stimulation cardiaques
US7488316B2 (en) Control of drug release by transient modification of local microenvironments
US6875208B2 (en) Microchip devices with improved reservoir opening
CA2577709C (fr) Dispositifs a reservoir dotes de plusieurs capuchons destines a la liberation controlee ou a l'exposition de contenus de reservoir
US20050267440A1 (en) Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
EP1365770A2 (fr) Dispositifs et methodes de gestion de la densite osseuse
Elman et al. Medical applications of implantable drug delivery microdevices based on MEMS (Micro-Electro-Mechanical-Systems)
Eltorai On-demand antibiotic-eluting microchip for implanted spinal screws
ES2969366T3 (es) Dispositivo y métodos de administración de fármacos con microchip de dos etapas
Maloney An implantable microfabricated drug delivery system
Manikandan Microchip: New Era in Novel Drug Delivery Systems-A Review
AU2002250038A1 (en) Devices and methods for management of bone density

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP